GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NVN Liquidation Inc (OTCPK:NOVNQ) » Definitions » 5-Year EBITDA Growth Rate

NVN Liquidation (NVN Liquidation) 5-Year EBITDA Growth Rate : 0.00% (As of Mar. 2023)


View and export this data going back to 2016. Start your Free Trial

What is NVN Liquidation 5-Year EBITDA Growth Rate?

NVN Liquidation's EBITDA per Share for the three months ended in Mar. 2023 was $-0.49.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Competitive Comparison of NVN Liquidation's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, NVN Liquidation's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NVN Liquidation's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NVN Liquidation's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where NVN Liquidation's 5-Year EBITDA Growth Rate falls into.



NVN Liquidation 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


NVN Liquidation  (OTCPK:NOVNQ) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.


NVN Liquidation 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of NVN Liquidation's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


NVN Liquidation (NVN Liquidation) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 64, Pittsboro, NC, USA, 27312
NVN Liquidation Inc Formerly Novan Inc is a dermatology company focused on developing and commercializing therapeutic products for skin diseases. It is developing SB206 as a topical prescription gel for the treatment of viral skin infections. The company's product portfolio includes; Wynzora Cream for the treatment of plaque psoriasis, Rhofade cream for the treatment of persistent facial erythema, Minolira tablets to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients, Cloderm cream for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Sitavig tablets for the treatment of recurrent herpes labialis in immunocompetent adults, and Nuvail nail solution for managing signs and symptoms of nail dystrophy.
Executives
Machelle Sanders director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
James L Bierman director 9120 LOCKWOOD BOULEVARD, MECHANICSVILLE VA 23116
John W Palmour director C/O CREE, INC., 4600 SILICON DRIVE, DURHAM NC 27703
John M. Gay officer: VP, Finance & Corp. Controller C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
A. Donofrio John officer: EVP, Chief Operating Officer C/O NOVAN, INC., 4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM NC 27703
Paula B Stafford director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Steven D Skolsky director TRIMERIS, INC., 3500 PARAMOUNT PARKWAY, MORRISVILLE NC 27560
Malin Life Sciences Holdings Ltd 10 percent owner 2 HARBOUR SQUARE, CROFTON ROAD, DUN LAOGHAIRE, CO, DUBLIN L2 ----
G. Kelly Martin director C/O NOVAN, INC., 4105 HOPSON RD, MORRISVILLE NC 27560
Robert Alexander Ingram director 280 S. MANGUM STREET, SUITE 350, DURHAM NC 27701
W Kent Geer director 7104 RAINWATER ROAD, RALEIGH NC 27615
Andrew Novak officer: Chief Accounting Officer C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Eugene Sun director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
James H. Goodnight Management Trust 10 percent owner 100 SAS CAMPUS DRIVE, CARY NC 27513
Donald R Parker 10 percent owner 100 SAS CAMPUS DRIVE, CARY NC 27513